BioSpace News Archive

This manufacturing agreement with Tetraphase is the result of a successful collaboration that started in 2014 with the clinical supply of eravacycline.

The agreement which became effective December 1, 2017, covers Teleflex’s full line of Active Humidification, Non Invasive Ventilation, and High Flow Nasal Cannula Therapy products.

The study is being conducted in the United States and top line data is expected in Q2 2018.

Cyclenium will receive an upfront payment and research funding from Ono, as well as development milestones and royalties on marketed products.

Neon Therapeutics announced the expansion of the company’s Board of Directors with the addition of leading experts in translational cancer drug discovery and corporate finance.

This agreement gives Palleon the exclusive rights to a patent portfolio that will facilitate the development of drugs that target Glycoimmune Checkpoints, a novel approach to overcoming resistance to first-generation immuno-oncology drugs.

FDA also granted OMIDRIA an additional six months of U.S. market exclusivity.

Relevium announce it has strengthened its balance sheet through the partial conversion of debentures into equity, and increased its cash position through the exercise of warrants and options.

The Company had not sold any shares, and will no longer offer any shares, under this program.

Janssen R&D today announced data from the Phase 3 ALCYONE study, showing that DARZALEX in combination with bortezomib, melphalan and prednisone significantly improved clinical outcomes, including reducing the risk of disease progression or death by 50 percent, in patients with newly diagnosed multiple myeloma who are ineligible for ASCT.